Literature DB >> 3496342

Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.

A M Vollmar, D E Banker, J Mendelsohn, H R Herschman.   

Abstract

Approximately equal amounts of 125I-mAb 225 (a monoclonal antibody recognizing the human epidermal growth factor receptor) and 125I-labeled epidermal growth factor (125I-EGF) were bound by HeLa cells. However, these two EGF receptor binding moieties had different fates after binding. Sixty percent of cell-associated 125I-EGF was internalized. The majority of internalized 125I was released from the cell within 2 hr. In contrast, whereas only 30% of bound 125I-mAb 225 was internalized by HeLa cells, the internalized radioactivity remained cell-associated. EGF and mAb 225 were used to construct ricin A-chain (RTA) conjugates. The two chimeric molecules, EGF-RTA and mAb 225-RTA, were equally toxic to human HeLa cells. EGF-RTA was also toxic to murine 3T3 cells. In contrast, mAb 225-RTA was not toxic to 3T3 cells, consistent with the human EGF-receptor specificity of mAb 225. Neither conjugate was cytotoxic to EGF receptor-deficient 3T3-NR6 cells. Rapidity and potency of protein synthesis inhibition of HeLa cells were equivalent for the two chimeric conjugates, as was the degree to which colony-forming ability was reduced. However, ammonium chloride enhanced the toxicity of EGF-RTA but not mAb 225-RTA, suggesting that the two toxic chimeric toxins--like the unconjugated receptor-binding moieties--are processed differently by HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496342     DOI: 10.1002/jcp.1041310314

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

Review 1.  Monoclonal antibodies to epidermal growth factor receptors in studies of receptor structure and function.

Authors:  T Kawamoto; G H Sato; K Takahashi; M Nishi; S Taniguchi; J D Sato
Journal:  Cytotechnology       Date:  1990-05       Impact factor: 2.058

2.  Effects of 131I-EGF on cultured human glioma cells.

Authors:  J Capala; M Pråhl; S Scott-Robson; J Pontén; B Westermark; J Carlsson
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 3.  EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.

Authors:  Jyoti Nautiyal; Shailender Singh Kanwar; Adhip P N Majumdar
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

Review 4.  Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

Authors:  Dennis J Yoon; Christina T Liu; Devin S Quinlan; Parsa M Nafisi; Daniel T Kamei
Journal:  Ann Biomed Eng       Date:  2011-02-25       Impact factor: 3.934

5.  Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site.

Authors:  R Pellegrini; F Centis; S Martignone; A Mastroianni; E Tagliabue; E Tosi; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells.

Authors:  A Andersson; J Capala; J Carlsson
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

Review 7.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.